Stock-Based Compensation: The estimated market value of stock options, warrants and other stock-based compensation given to employees and/or vendors.
Kairos Pharma, Ltd. (KAPA) Stock-Based Compensation data is not available for the most recently reported fiscal quarter, ending 2025-09-30.
| Income Statement Financials | |
-- |
|
$-1.40M |
|
-- |
|
-- |
|
$1.44M |
|
$-1.44M |
|
$0.04M |
|
$-1.40M |
|
$-1.40M |
|
$-1.40M |
|
$-1.40M |
|
$-1.40M |
|
$-1.40M |
|
$-1.44M |
|
$-0.73M |
|
20.21M |
|
20.21M |
|
$-0.07 |
|
$-0.07 |
|
| Balance Sheet Financials | |
$6.66M |
|
-- |
|
$1.41M |
|
$8.07M |
|
$0.40M |
|
-- |
|
-- |
|
$0.40M |
|
$7.66M |
|
$7.56M |
|
$7.66M |
|
20.82M |
|
| Cash Flow Statement Financials | |
$-2.36M |
|
-- |
|
$6.66M |
|
$1.27M |
|
$5.58M |
|
$4.30M |
|
|
Stock-Based Compensation |
-- |
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
16.56 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-2.36M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-18.24% |
|
-18.49% |
|
-17.33% |
|
-18.24% |
|
$0.37 |
|
$-0.12 |
|
$-0.12 |
|